Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksApq Global Regulatory News (APQ)

  • There is currently no data for APQ

Company Update

7 Feb 2025 07:00

RNS Number : 2522W
APQ Global Limited
07 February 2025
 

APQ Global Limited

 

("APQ Global" or the "Company")

 

Company Update

 

The new US Administration has taken the sledgehammer to international aid and foreign assistance more broadly. While the immediate cashflow implications are manageable for Delphos, the core driver of the Company's performance, it has created a very challenging environment. The Company believes that through a combination of cash flow generation and a partial refinancing, it expects to meet its obligation to repay the CULS holders by no later than 31 March 2025, but the risk to this has meaningfully increased. The refinancing is required to satisfy the CULS repayment and the Company continues to engage with multiple parties and discussions with regards to a potential full or partial refinancing remain ongoing. The outstanding principal amount due to CULS holders is currently £26.1 million.

 

On the capital raising front, Delphos is currently executing 44 capital raising mandates (versus 47 as at 23 December 2024). Seventy five percent (75%) of Delphos' pipeline revenue is dependent on US Government agency departments and developments announced by the new US Administration casts uncertainty on the timing of realising the expected cashflows. At this stage, these contracts remain fully in place and the only immediate impact is a slowdown in execution, as no explicit policy changes have yet been implemented. The pipeline is well aligned with the policy initiatives of the new US Administration (critical minerals, infrastructure and security considerations) and the Company expects a significant increase in US Government support for these projects, however, it remains to be seen how fast existing transactions will be executed and the timing of the receipt of fees and commissions.

 

The US policy framework remains extremely fluid and unpredictable, and circumstances can change quickly. As a result of executive orders signed by the new US Administration, Delphos saw an immediate pause on two-thirds of its transaction advisory contracts, which have now been cancelled (representing c.$5.0million in contract value). The remaining transaction advisory contracts are expected to be cancelled in the coming weeks. These contracts were being executed and have been aborted. The immediate cashflow impact, while material, is so far manageable but we remain cognisant of potential further damage beyond the cancellation of existing transaction advisory contracts.

 

Delphos has made a hard pivot away from official financing sources towards private sector funding over the past six weeks and expect meaningful cash generation in the very near term. While the Company believes that it is well-placed to execute these transactions, the overall policy environment in the US and the reaction of other countries to it will continue to provide significant challenges.

 

In terms of the expected revenue, the table below shows the realised cashflows for December 2024 and January 2025 and management's revised estimates based on the status of the deals in execution, compared with the estimates disclosed in its trading update contained within the interim results published on 29 November 2024 and reiterated in the Company's book value announcement on 23 December 2024:

 

$

Realised Cash Inflows (December 2024 - January 2025) and Revised Estimate (February 2025 - September 2026)

Previous Estimate (29 November 2024)

December 2024

614,000

2,732,439

January 2025

487,000

16,200,000

February 2025

14,520,000

16,500,000

March 2025

11,119,000

4,300,000

April 2025 - September 2026

60,672,000

73,840,000

Total

87,412,000

113,572,439

 

As detailed above, the ongoing impact of the new US Administration has given rise to greater uncertainty which may continue to impact near-term expected cash inflows.

 

 

In the medium term, the Company believes its prospects remain solid and expects the transaction advisory business to bounce back when the US Government reassesses its priorities. On the capital raising side, borrowers are likely to be amenable to accept higher borrowing costs and the Company expects to draw in more private sector capital.

 

At the end of January 2025, the Group held approximately $3.2 million in cash versus $4.4 million at the end of November 2024 reflecting payment delays and seasonal factors.

 

The Company expects to publish its book value as at 31 December 2024 by the end of February 2025.

 

- End -

 

 

For further enquiries, please contact:

 

APQ Global Limited Bart Turtelboom

020 3478 9708

 

 

Singer Capital Markets - Nominated Adviser and Broker James Maxwell/Sam Greatrex

020 7496 3000

Suntera - TISE sponsor Claire Torode

01481 737 277

Investor Relations

IR@APQGlobal.com

 

 

Notes to Editors

 

APQ Global Limited

 

APQ Global (ticker: APQ LN) is an investment company incorporated in Guernsey. The Company focuses its investment activities globally (in Asia, Latin America, Eastern Europe, the Middle East, Africa and the Channel Islands, particularly). The objective of the Company is to steadily grow its earnings to seek to deliver attractive returns and capital growth through a combination of building growing businesses as well as earning revenue from income generating operating activities in capital markets. APQ Global run a well-diversified and liquid portfolio, take strategic stakes in selected businesses and plan to take operational control of companies through the acquisition of minority and majority stakes in companies with a focus on emerging markets. For more information, please visit apqglobal.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFFDFDIRIIE
Date   Source Headline
8th Apr 20257:00 amRNSCancellation - APQ Global Limited
31st Mar 20252:30 pmRNSResult of EGM & CULS Holder Meeting
6th Mar 20251:30 pmRNSPublication of Circular & Notice of Meetings
6th Mar 202512:15 pmRNSResult of EGM
14th Feb 20254:00 pmRNSPublication of Circular & Notice of EGM
7th Feb 20257:00 amRNSCompany Update
23rd Dec 20243:16 pmRNSBook Value Report
16th Dec 20243:30 pmRNSResult of AGM
4th Dec 20244:30 pmRNSDirector/PDMR Shareholding
4th Dec 202411:16 amRNSHolding(s) in Company
2nd Dec 20247:30 amRNSRestoration - APQ Global Limited
29th Nov 20247:30 amRNSRestoration - APQ Global Limited
29th Nov 20247:25 amRNSRestoration to trading on AIM & ISM
29th Nov 20247:00 amRNSInterim Results
22nd Nov 202412:30 pmRNSNotice of AGM
15th Nov 20245:30 pmRNSFinal results for the year to 31 December 2023
30th Sep 20242:00 pmRNSResult of CULS Meeting
26th Sep 20249:30 amRNSProposed Increased Initial Payment to CULS Holders
24th Sep 20241:00 pmRNSRefinancing Update & Proposed CULS Holder Payment
16th Sep 20244:00 pmRNSUnaudited Final Results
9th Sep 20242:30 pmRNSBook Value Report
6th Sep 20245:15 pmRNSNotice of CULS Holder Meeting & Update
31st Jul 20247:00 amRNSPublication of Annual Report & Accounts
9th Jul 20243:00 pmRNSChange of Registered Office
1st Jul 20247:30 amRNSSuspension - APQ GLOBAL LIMITED
25th Jun 20244:00 pmRNSPublication of Annual Report & Accounts
13th Jun 20244:30 pmRNSChange of Registered Office
24th May 20247:00 amRNSBook Value Report
3rd Apr 20247:00 amRNSTrading Update
22nd Mar 20247:00 amRNSBook Value Report
6th Feb 20245:00 pmRNSBook Value Report
19th Dec 20235:00 pmRNSBook Value Report
20th Nov 20235:06 pmRNSBook Value Report
17th Oct 20235:00 pmRNSBook Value Report
27th Sep 202312:00 pmRNSBook Value Report
21st Sep 20231:00 pmRNSDirectorate Change
17th Aug 20235:00 pmRNSBook Value Report
9th Aug 20235:01 pmRNSResult of AGM
14th Jul 20231:00 pmRNSBook Value Report
10th Jul 202312:00 pmRNSNotice of AGM
22nd Jun 20231:00 pmRNSBook Value Report
6th Jun 20237:00 amRNSFinal results for the year to 31 December 2022
17th May 20231:00 pmRNSBook Value Report
20th Apr 202310:00 amRNSResult of Tender Offer for CULS
18th Apr 20237:00 amRNSBook Value Report
3rd Apr 20237:00 amRNSTender Offer for CULS
17th Mar 20237:00 amRNSBook Value Report
21st Feb 20239:00 amRNSBook Value Report
27th Jan 20237:00 amRNSBook Value Report
16th Dec 20225:00 pmRNSBook Value Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.